How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。